EIM
MRNA icon

Essex Investment Management’s Moderna MRNA Stock Holding History

Essex Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,300
Closed -$1.85M – 411
2021
Q4 		$1.85M Sell
7,300
-3,800
-34% -$1.11M 0.21% 152
2021
Q3 		$4.27M Sell
11,100
-3,900
-26% -$1.44M 0.52% 51
2021
Q2 		$3.52M Hold
15,000
– – 0.41% 74
2021
Q1 		$1.96M Sell
15,000
-6,262
-29% -$907K 0.24% 143
2020
Q4 		$2.22M Buy
21,262
+13,262
+166% +$1.34M 0.28% 115
2020
Q3 		$566K Buy
+8,000
New +$558K 0.08% 287
2019
Q3 		– Sell
-22,475
Closed -$329K – 492
2019
Q2 		$329K Sell
22,475
-6,336
-22% -$136K 0.05% 334
2019
Q1 		$586K Buy
28,811
+19,260
+202% +$357K 0.09% 248
2018
Q4 		$146K Buy
+9,551
New +$157K 0.02% 358

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Essex Investment Management's MRNA Position: Q1 2022 in Review

Essex Investment Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 7,300 shares — an estimated $1.85M sold.

Essex Investment Management first reported a position in MRNA in Q4 2018 and held it in 9 quarters. The position peaked at $4.27M in Q3 2021. 1,007 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Essex Investment Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Essex Investment Management sold 7,300 Moderna shares in Q1 2022, an estimated $1.85M.
  • Essex Investment Management first reported a position in Moderna in Q4 2018 and held it in 9 quarters.
  • Essex Investment Management's Moderna position peaked at $4.27M in Q3 2021.
  • 1,007 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Essex Investment Management's 13F filing for Q1 2022, filed 9 May 2022.